Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. [electronic resource]
Producer: 20160209Description: e272-4 p. digitalISSN:- 1592-8721
- Antineoplastic Agents -- therapeutic use
- Diarrhea -- etiology
- Drug Administration Schedule
- Edema -- etiology
- Fatigue -- etiology
- Female
- Gene Expression
- HSP90 Heat-Shock Proteins -- antagonists & inhibitors
- Humans
- Isoxazoles -- therapeutic use
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Lymphoma, T-Cell, Peripheral -- drug therapy
- Male
- Recurrence
- Remission Induction
- Resorcinols -- therapeutic use
- Retrospective Studies
- Survival Analysis
- Thrombocytopenia -- etiology
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Letter
There are no comments on this title.
Log in to your account to post a comment.